Literature DB >> 27717666

Neutralizing capacity of monoclonal and polyclonal anti-natalizumab antibodies: The immune response to antibody therapeutics preferentially targets the antigen-binding site.

Karin A van Schie1, Simone Kruithof1, Pauline A van Schouwenburg1, Anke Vennegoor2, Joep Killestein2, Gertjan Wolbink3, Theo Rispens4.   

Abstract

Mesh：

Substances：

Year:  2016        PMID： 27717666     DOI： 10.1016/j.jaci.2016.09.014

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN： 0091-6749            Impact factor:   10.793


× No keyword cloud information.
  4 in total

1.  Interleukin 31 in insect bite hypersensitivity-Alleviating clinical symptoms by active vaccination against itch.

Authors:  Florian Olomski; Victoria Fettelschoss; Sigridur Jonsdottir; Katharina Birkmann; Franziska Thoms; Eliane Marti; Martin F Bachmann; Thomas M Kündig; Antonia Fettelschoss-Gabriel
Journal:  Allergy       Date:  2020-02-06       Impact factor: 13.146

2.  Biased anti-idiotype response in rabbits leads to high-affinity monoclonal antibodies to biologics.

Authors:  Christina Großerichter-Wagener; Dorien Kos; Astrid van Leeuwen; Lisanne Dijk; Jorn Jeremiasse; Floris C Loeff; Theo Rispens
Journal:  MAbs       Date:  2020 Jan-Dec       Impact factor: 5.857

3.  Assessment of immunogenicity from galcanezumab phase 3 trials in patients with episodic or chronic migraine.

Authors:  James M Martinez; Nada Hindiyeh; Greg Anglin; Kavita Kalidas; Michael E Hodsdon; William Kielbasa; Brian A Moser; Eric M Pearlman; Sandra Garces
Journal:  Cephalalgia       Date:  2020-04-27       Impact factor: 6.292

Review 4.  Immunogenicity of TNF-Inhibitors.

Authors:  Sadaf Atiqi; Femke Hooijberg; Floris C Loeff; Theo Rispens; Gerrit J Wolbink
Journal:  Front Immunol       Date:  2020-02-26       Impact factor: 7.561
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.